ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Incidence Reduced 45% In Tamoxifen Arm Of BCPT; Trial Unblinded

April 10, 1998

Cancer Information Available By Fax

May 3, 1991

Frei, Freireich Share One GM Prize; Ames, Erikson Win Others

June 17, 1983

Study Shows MammaPrint Test Can Predict 25-Year Risk Levels

February 28, 2014

New Surgery Grant Applications To Be Reviews By Special Ad Hoc Study Section; 54 Submitted

June 22, 1979

Radiation Doesn’t Add Benefit For Early Endometrial Cancer

June 29, 2007